Press Releases

Date Title and Summary Additional Formats
Toggle Summary Schwarz Pharma's KUDCo Not Seeking to Temporarily Halt Mylan's Omeprazole Sales
Schwarz Pharma's KUDCo Not Seeking to Temporarily Halt Mylan's Omeprazole Sales PITTSBURGH--(BUSINESS WIRE)--Aug. 8, 2003--Contrary to the implications in Schwarz Pharma's August 7, 2003 press release, and after consultation with KUDCo's attorneys, Mylan Laboratories Inc.
View HTML
Toggle Summary Mylan Announces Omeprazole Launch
Mylan Announces Omeprazole Launch PITTSBURGH--(BUSINESS WIRE)--Aug. 4, 2003--Mylan Laboratories Inc. (NYSE: MYL) today announced that its wholly-owned subsidiary, Mylan Pharmaceuticals Inc., has begun the sale of 10 mg and 20 mg omeprazole delayed-release capsules.
View HTML
Toggle Summary Mylan Reports Record EPS, Revenues and Net Earnings for the First Quarter of Fiscal 2004 and Increases Annual Earnings Guidance
Mylan Reports Record EPS, Revenues and Net Earnings for the First Quarter of Fiscal 2004 and Increases Annual Earnings Guidance Financial Highlights -- Record diluted earnings per share of $0.46 for the first quarter of fiscal 2004, compared to $0.32 for the same prior year period.
View HTML
Toggle Summary Mylan Announces First Quarter Fiscal 2004 Earnings Release Date and Conference Call
Mylan Announces First Quarter Fiscal 2004 Earnings Release Date and Conference Call PITTSBURGH--(BUSINESS WIRE)--July 14, 2003--Mylan Laboratories Inc. (NYSE: MYL) announced today that it will release its first quarter fiscal 2004 financial results before the market opens on Wednesday, July 23,
View HTML
Toggle Summary Mylan's Apomorphine NDA Advances in FDA Review Process
Mylan's Apomorphine NDA Advances in FDA Review Process PITTSBURGH--(BUSINESS WIRE)--July 10, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that its subsidiary, Bertek Pharmaceuticals Inc., has received an approvable letter from the Food and Drug Administration (FDA) for its New Drug
View HTML
Toggle Summary Mylan Acknowledges FDA Letter, Which Will Not Impact the Commercial Status of Amnesteem
Mylan Acknowledges FDA Letter, Which Will Not Impact the Commercial Status of Amnesteem PITTSBURGH--(BUSINESS WIRE)--June 19, 2003--Mylan Laboratories' (NYSE:MYL) brand subsidiary, Bertek Pharmaceuticals received an Untitled Letter from the United States Food and Drug Administration (FDA) regarding
View HTML
Toggle Summary Mylan Receives FDA Approval for Mirtazapine Tablets
Mylan Receives FDA Approval for Mirtazapine Tablets PITTSBURGH, Jun 19, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Mirtazapine Tablets in 15 mg, 30 mg
View HTML
Toggle Summary Mylan Declares Regular Quarterly Cash Dividend
Mylan Declares Regular Quarterly Cash Dividend PITTSBURGH--(BUSINESS WIRE)--June 16, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of $0.0333 per share will be paid on July 15, 2003, to shareholders of record on June 30, 2003.
View HTML
Toggle Summary Mylan Announces Approval for Omeprazole Delayed-release Capsules
Mylan Announces Approval for Omeprazole Delayed-release Capsules PITTSBURGH, Jun 2, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Omeprazole
View HTML
Toggle Summary Mylan Reports Record EPS, Revenues and Net Earnings For the Fourth Quarter and Fiscal 2003
Mylan Reports Record EPS, Revenues and Net Earnings For the Fourth Quarter and Fiscal 2003 PITTSBURGH--(BUSINESS WIRE)--May 8, 2003--Mylan Laboratories Inc. (NYSE: MYL) Financial Highlights -- Record diluted earnings per share of $1.45 for fiscal 2003 and $.40 for the fourth quarter, compared to
View HTML